Original Source(s)
Related Content
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min
Lactate Biomarker May Predict Outcomes in Cardiogenic Shock
A review of cardiogenic shock studies suggests serial lactate measurements provide more prognostic information than isolated values and may better reflect treatment response.
June 23, 2026
-
4 min
FDA Monthly Preview: Key July Decisions to Watch
Several FDA decisions across multiple specialties are expected this month.
June 26, 2026
-
5 min